Guide

Legal Psychedelics in the US: State by State Status and Pathways

A definitive, plain-English guide to the legal landscape of psychedelics in the United States, with a focus on federal law, state-level exceptions, and the future of therapeutic access.

Last updated November 13, 2026 810-word guide Editor The Psychedelic Journal

Are Psychedelics Legal in the United States?

No, psychedelics such as psilocybin are not legal for general use in the United States. Under federal law, classic psychedelics—including psilocybin (the active compound in "magic mushrooms"), LSD (lysergic acid diethylamide), DMT (dimethyltryptamine), and mescaline—are classified as Schedule I substances under the Controlled Substances Act (CSA). This means they are considered to have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. As of this writing, no psychedelic substance has received full approval from the US Food and Drug Administration (FDA) for any indication.

However, a small but growing number of states have enacted exceptions for specific psychedelic substances, most notably psilocybin, for supervised therapeutic use. This is a rapidly evolving area of law. This article provides general information only and does not constitute legal advice.

Federal Law: The Baseline for Psychedelics

The federal government, through the Drug Enforcement Administration (DEA) and the Controlled Substances Act, sets the baseline for drug legality in the US. As of now:

There are no FDA-approved psychedelic medicines as of this writing. Compass Pathways' COMP360 psilocybin therapy and Usona Institute's IPR001 are in Phase 3 trials, with FDA submissions underway, but approval and rescheduling have not yet occurred. For a full research landscape, see our psychedelic research landscape guide.

State-by-State Exceptions: Oregon and Colorado Lead

While federal law is supreme, states can create their own exceptions, especially around medical or supervised adult use. As of now, only two states have established legal frameworks for psilocybin therapy:

Oregon: Measure 109

Oregon was the first state to legalize supervised psilocybin services for adults 21 and over, via Measure 109 (2020). The program launched in 2023. Key features:

For more on Oregon's legal framework, see our psychedelic law guide.

Colorado: Proposition 122

Colorado voters passed Proposition 122 in 2022, launching a regulated adult-use psilocybin program in 2024-2025. The law:

Other states have considered or enacted limited decriminalization (e.g., personal use in some cities), but no other state currently allows legal, regulated access to psychedelics for therapy or adult use.

Decriminalization vs. Legalization: What’s the Difference?

It is important to distinguish between decriminalization and legalization:

In most US jurisdictions, psychedelics remain illegal and subject to criminal penalties. For more on the legal landscape, see our psychedelic law and briefing sections.

Therapeutic Access: FDA Pathways and Clinical Trials

While state programs are pioneering regulated access, the main pathway to widespread legal psychedelic therapy remains through FDA approval and subsequent rescheduling. As of now:

For a deeper dive into research, see our research landscape and briefing feeds.

What Should Researchers, Investors, and Patients Do Next?

The US legal landscape for psychedelics is in flux. Key points for stakeholders:

Always consult a qualified attorney before making decisions based on state or federal drug laws.